Bayer Cropscience Limited (BAYERCROP) - Total Assets
Based on the latest financial reports, Bayer Cropscience Limited (BAYERCROP) holds total assets worth Rs51.91 Billion INR (≈ $561.39 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Bayer Cropscience Limited shareholders equity for net asset value and shareholders' equity analysis.
Bayer Cropscience Limited - Total Assets Trend (2004–2025)
This chart illustrates how Bayer Cropscience Limited's total assets have evolved over time, based on quarterly financial data.
Bayer Cropscience Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Bayer Cropscience Limited's total assets of Rs51.91 Billion consist of 85.2% current assets and 14.8% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs6.93 Billion | 17.0% |
| Accounts Receivable | Rs9.57 Billion | 18.3% |
| Inventory | Rs23.62 Billion | 45.0% |
| Property, Plant & Equipment | Rs4.27 Billion | 8.2% |
| Intangible Assets | Rs1.36 Billion | 2.6% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2004–2025)
This chart illustrates how Bayer Cropscience Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BAYERCROP company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bayer Cropscience Limited's current assets represent 85.2% of total assets in 2025, an increase from 73.0% in 2004.
- Cash Position: Cash and equivalents constituted 17.0% of total assets in 2025, up from 11.5% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2004.
- Asset Diversification: The largest asset category is inventory at 45.0% of total assets.
Bayer Cropscience Limited Competitors by Total Assets
Key competitors of Bayer Cropscience Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Yangnong Chemical Co Ltd
SHG:600486
|
China | CN¥18.24 Billion |
|
Chengdu Wintrue Holding Co Ltd
SHE:002539
|
China | CN¥25.55 Billion |
|
Hubei Yihua Chemical Industry Co Ltd
SHE:000422
|
China | CN¥45.04 Billion |
|
Shaanxi Meibang Pharmaceutical Group Co Ltd
SHG:605033
|
China | CN¥1.91 Billion |
|
Fanli Digital Technology Co Ltd
SHG:600228
|
China | CN¥575.15 Million |
|
Insumos Agroquimicos SA
BA:INAG
|
Argentina | AR$45.35 Billion |
|
Cho Bi
KO:001550
|
Korea | ₩121.71 Billion |
|
Amoeba SA
PA:ALMIB
|
France | €6.37 Million |
Bayer Cropscience Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.29 | 2.22 | 2.15 |
| Quick Ratio | 1.43 | 1.57 | 1.58 |
| Cash Ratio | 0.34 | 0.44 | 0.00 |
| Working Capital | Rs24.82 Billion | Rs25.23 Billion | Rs18.58 Billion |
Bayer Cropscience Limited - Advanced Valuation Insights
This section examines the relationship between Bayer Cropscience Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.95 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 14.1% |
| Total Assets | Rs52.46 Billion |
| Market Capitalization | $2.32 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Bayer Cropscience Limited's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Bayer Cropscience Limited's assets grew by 14.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Bayer Cropscience Limited (2004–2025)
The table below shows the annual total assets of Bayer Cropscience Limited from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs52.46 Billion ≈ $567.32 Million |
+14.11% |
| 2024-03-31 | Rs45.97 Billion ≈ $497.16 Million |
-1.74% |
| 2023-03-31 | Rs46.79 Billion ≈ $505.97 Million |
+7.48% |
| 2022-03-31 | Rs43.53 Billion ≈ $470.75 Million |
+2.68% |
| 2021-03-31 | Rs42.39 Billion ≈ $458.46 Million |
+10.52% |
| 2020-03-31 | Rs38.36 Billion ≈ $414.82 Million |
+32.20% |
| 2019-03-31 | Rs29.02 Billion ≈ $313.79 Million |
+14.47% |
| 2018-03-31 | Rs25.35 Billion ≈ $274.13 Million |
-10.29% |
| 2017-03-31 | Rs28.25 Billion ≈ $305.56 Million |
+15.88% |
| 2016-03-31 | Rs24.38 Billion ≈ $263.69 Million |
-12.09% |
| 2015-03-31 | Rs27.74 Billion ≈ $299.95 Million |
+16.20% |
| 2014-03-31 | Rs23.87 Billion ≈ $258.13 Million |
-1.16% |
| 2013-03-31 | Rs24.15 Billion ≈ $261.17 Million |
+31.20% |
| 2012-03-31 | Rs18.41 Billion ≈ $199.06 Million |
+16.93% |
| 2011-03-31 | Rs15.74 Billion ≈ $170.25 Million |
+45.34% |
| 2010-03-31 | Rs10.83 Billion ≈ $117.14 Million |
+15.57% |
| 2009-03-31 | Rs9.37 Billion ≈ $101.36 Million |
+9.68% |
| 2008-03-31 | Rs8.55 Billion ≈ $92.42 Million |
+29.61% |
| 2007-03-31 | Rs6.59 Billion ≈ $71.30 Million |
+0.02% |
| 2006-03-31 | Rs6.59 Billion ≈ $71.29 Million |
+14.74% |
| 2005-03-31 | Rs5.75 Billion ≈ $62.13 Million |
-20.11% |
| 2004-03-31 | Rs7.19 Billion ≈ $77.77 Million |
-- |
About Bayer Cropscience Limited
Bayer CropScience Limited engages in the manufacture, sale, and distribution of insecticides, fungicides, herbicides, and various other agrochemical products and hybrid corn seeds in India, Germany, Bangladesh, and internationally. It provides medicines in the therapeutic areas of cardiology, gynecology, diabetes, oncology, and ophthalmology; and computed tomography, X-Ray, and magnetic resonance… Read more